Zonisamide improves motor function in Parkinson disease
@article{Murata2007ZonisamideIM, title={Zonisamide improves motor function in Parkinson disease}, author={Miho Murata and Kazuko Hasegawa and Ichiro Kanazawa}, journal={Neurology}, year={2007}, volume={68}, pages={45 - 50} }
Objective: To evaluate the efficacy, safety and tolerability of daily doses of 25, 50, and 100 mg of zonisamide (ZNS) administered as adjunctive treatment in patients with Parkinson disease (PD). Methods: We conducted a multicenter, randomized, double-blind, parallel-treatment, placebo-controlled study in Japan. Patients with PD who showed insufficient response to levodopa treatment were given placebo for 2 weeks and then treated for 12 weeks with 25, 50, or 100 mg/day of ZNS or placebo, in…
143 Citations
Adjunct zonisamide to levodopa for DLB parkinsonism
- Medicine, PsychologyNeurology
- 2018
This study provides Class I evidence that zonisamide (adjunctive to levodopa) improves parkinsonism and is well-tolerated in patients with DLB.
Zonisamide: in Parkinson's disease.
- Medicine, PsychologyCNS drugs
- 2009
Zonisamide 25 mg once daily as adjunctive therapy with levodopa was generally well tolerated by patients with Parkinson's disease and was associated with increased striatal dopamine levels in animal models.
Zonisamide for the Treatment of Parkinson Disease: A Current Update
- Biology, PsychologyFrontiers in Neuroscience
- 2020
Based on adequate randomized controlled trials, zonisamide is considered a safe and efficacious add-on treatment in Parkinson disease and may play a beneficial role in improving non-motor symptoms in PD, including impulsive–compulsive disorder, rapid eye movement sleep behavior disorder, and dementia.
Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials
- Medicine, PsychologyJournal of Alzheimer's disease : JAD
- 2020
The findings indicate that zonisamide improved parkinsonism with DLB without deterioration of cognitive function and or worsening behavioral and psychological symptoms of dementia.
Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.
- MedicineParkinsonism & related disorders
- 2019
Zonisamide for the treatment of Parkinson’s disease
- Medicine, PsychologyExpert review of neurotherapeutics
- 2007
It is expected that zonisamide will be safe and tolerated in patients with PD, as it has been used as an antiepileptic for more than 15 years; however, further studies are required to evaluate its safety and tolerability in the treatment of PD.
The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data
- PsychologyDrug design, development and therapy
- 2021
Zonisamide significantly improved the Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) without affecting the Mini-Mental State Examination (MMSE) or Neuropsychiatry Inventory-10 (NPI-10) scores at week 12.
Zonisamide for Essential Tremor
- MedicineClinical neuropharmacology
- 2007
Zonisamide significantly (albeit modestly) improved the TSGRS scores in this small group of medically refractory subjects who completed the evaluation, however, clinical impressions did not improve, and the study was complicated by a large dropout rate caused by subjective lack of efficacy and by AEs.
Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
- MedicineParkinsonism & related disorders
- 2018
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
- Medicine, PsychologyParkinsonism & related disorders
- 2020
References
SHOWING 1-10 OF 19 REFERENCES
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
- Medicine, PsychologyThe Lancet
- 2005
Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
- Biology, PsychologyCurrent pharmaceutical design
- 2004
It is suggested that the activation of dopamine synthesis and the moderate level of MAOB inhibition are main mechanisms of ZNS effects on PD.
Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol.
- MedicineParkinsonism & related disorders
- 2005
Zonisamide has beneficial effects on Parkinson's disease patients
- Psychology, MedicineNeuroscience Research
- 2001
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
- Medicine, BiologyArchives of neurology
- 2005
This study confirms that a continuous levodopa infusion is associated with reduced motor complications compared with the standard oral formulation of the drug in patients with advanced PD.
Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease
- Medicine, PsychologyMovement disorders : official journal of the Movement Disorder Society
- 2003
We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to…
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson’s activity
- BiologyJournal of Neural Transmission
- 2004
Results support previously reported findings and provide additional evidence that the anticonvulsant ZNS appears to possess anti-Parkinson’s properties and could be a novel agent for the treatment of PD that could delay the use of or reduce the amount of levodopa needed to treat patients with PD.
Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ ependent dopamine release
- Biology, ChemistryEpilepsy Research
- 1992